In this episode, Amplia Therapeutics' latest ASX announcement: a signed Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company. The two companies will evaluate the combination of Amplia's investigational FAK inhibitor, narmafotinib, with Lilly's investigational KRAS G12C inhibitor, olomorasib, in patients with advanced-stage non-small cell lung cancer.